Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.

International journal of physiology, pathophysiology and pharmacology Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
{"title":"Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.","authors":"Rujittika Mungmunpuntipantip,&nbsp;Viroj Wiwanitkit","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>COVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two doses of COVID-19 vaccines are required. Booster immunization is generally required when immunity has deteriorated.</p><p><strong>Methods: </strong>The effectiveness of the alternate boost immunization protocol is still unknown. The authors of this study used a cost-effectiveness analysis, which is a retrospective analysis on datasets on cost and effectiveness, to examine the projected cost-effectiveness of boosting COVID-19 vaccination by a fourth dose.</p><p><strong>Results: </strong>The cost-effectiveness of the fourth-dose COVID booster vaccine was found to be higher in this study.</p><p><strong>Conclusion: </strong>It could imply that vaccinating against the current pandemic of the novel form, omicron, with the additional COVID-19 vaccine is a smarter idea.</p>","PeriodicalId":14352,"journal":{"name":"International journal of physiology, pathophysiology and pharmacology","volume":"14 4","pages":"272-275"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490214/pdf/ijppp0014-0272.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of physiology, pathophysiology and pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: COVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two doses of COVID-19 vaccines are required. Booster immunization is generally required when immunity has deteriorated.

Methods: The effectiveness of the alternate boost immunization protocol is still unknown. The authors of this study used a cost-effectiveness analysis, which is a retrospective analysis on datasets on cost and effectiveness, to examine the projected cost-effectiveness of boosting COVID-19 vaccination by a fourth dose.

Results: The cost-effectiveness of the fourth-dose COVID booster vaccine was found to be higher in this study.

Conclusion: It could imply that vaccinating against the current pandemic of the novel form, omicron, with the additional COVID-19 vaccine is a smarter idea.

针对COVID-19组粒变体的第四剂COVID-19疫苗的预期成本效益:初步报告
目标:COVID-19免疫接种已被证明可有效预防COVID-19。传统上,需要两剂COVID-19疫苗。当免疫力下降时,通常需要加强免疫。方法:交替强化免疫方案的有效性尚不清楚。本研究的作者使用了成本效益分析,这是对成本和效益数据集的回顾性分析,以检查增加第四剂COVID-19疫苗接种的预计成本效益。结果:本研究发现第四剂COVID加强疫苗的成本-效果更高。结论:这可能意味着,用额外的COVID-19疫苗接种当前流行的新形式的omicron疫苗是一个更明智的主意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信